871589-86-5

Upstream product

• 171860-41-6 (S,S)-4-methyl-5-oxo-2-phenyl-oxazolidine-3-carboxylic acid benzyl ester 
• 34250-16-3 3-oxocyclopent-1-ene-1-carbonitrile 
• 368-63-8 (R)-[3,5-bis(trifluoromethyl)phenyl]ethanol 
• 10481-34-2 2-bromo-2-cyclopenten-1-one 
• 930-30-3 cyclopent-2-enone 
• 1007593-16-9 C₄₁H₃₆F₇NO₆ 
• 1007593-46-5 C₂₃H₂₀F₇IO₂ 
• 1007592-25-7 C₂₃H₂₁F₇O₂ 
• 1007591-49-2 C₂₃H₂₁F₇O₂ 
• 1007592-12-2 C₁₇H₁₆F₆O₂ 
• 1007591-98-1 C₁₆H₁₃F₆NO 
• 1007591-93-6 C₁₇H₁₃NO₂ 
• 1007591-88-9 (S)-3-hydroxycyclopent-1-enecarbonitrile 
• 871589-85-4 (3R,5R)-5-(((1R),(2R),(3S))-3-((1R)-1-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-2-(4-fluorophenyl)cyclopentan-1-yl)-3-carboxy-3-methylpyrrolidin-2-one 

Relevant academic research and scientific papers

Enantioselective, biocatalytic reduction of 3-substituted cyclopentenones: Application to the asymmetric synthesis of an hNK-1 receptor antagonist

A convergent and enantioselective route to the hNK-1 receptor antagonist (1) is described, which sets all six stereogenic centers with high diastereoselectivity and delivers 1 in only 11 steps and 23% overall yield. The process was enabled by the developm

Combination Therapy for the Treatment of Urinary Frequency, Urinary Urgency and Urinary Incontinence

This invention concerns compositions for the treatment of urinary frequency, urinary urgency and urinary incontinence comprising (R)-N-[4-[2-[[2-hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]phenyl]-4-[4-(4-tri-fluoromethylphenyl)thiazol-2-yl]benzenesulfonami

PROCESS FOR MAKING LACTAM TACHYKININ RECEPTOR ANTAGONISTS

The present invention is directed to a process for preparing certain α,α disubstituted γ-lactam derivatives that are useful as neurokinin-1 (NK-1) receptor antagonists, and inhibitors of tachykinin and in particular substance P. The compounds are useful i

COMBINATION THERAPY FOR THE TREATMENT OF URINARY FREQUENCY, URINARY URGENCY AND URINARY INCONTINENCE

This invention concerns compositions for the treatment of urinary frequency, urinary urgency and urinary incontinence comprising a selected antagonist of the NK-1 receptor or a pharmaceutically acceptable salt thereof and an anti-muscarinic agent or a pha

Lactam tachykinin receptor antagonists

The present invention is directed to certain lactam compounds which are useful as neurokinin-1 (NK-1) receptor antagonists, and inhibitors of tachykinin and in particular substance P. The invention is also concerned with pharmaceutical formulations compri